Yogen Saunthararajah

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (25)

• FLT3-ITD signals for CEBPA and p53 proteolysis by the ubiquitin-proteosome pathway
  2026 DOI: 10.21203/rs.3.rs-10436387/v1
  +Save
• H2BE113K mutation promotes breast cancer metastasis through modulating chromatin dynamics
  Science Advances 2026 DOI: 10.1126/sciadv.adx4982
  +Save
• Informing the debate: hypomethylating agents/venetoclax or intensive chemotherapy to treat acute myeloid leukemias
  Leukemia & Lymphoma 2026 DOI: 10.1080/10428194.2026.2707894
  +Save
• Data from A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML
  2025 DOI: 10.1158/1078-0432.c.6706696
  +Save
• Table S1 from A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML
  2025 DOI: 10.1158/1078-0432.30709263
  +Save
• Epigenetic drug remedies for SCD root cause pathophysiology
  Blood 2025 DOI: 10.1182/blood.2025029447
  +Save
• A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort
  Blood 2024 DOI: 10.1182/blood.2024025834
  +Save
• Oncotherapy resistance explained by Darwinian and Lamarckian models
  Journal of Clinical Investigation 2024 DOI: 10.1172/JCI179788
  +Save
• Table S1 from A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML
  2023 DOI: 10.1158/1078-0432.23814743.v1
  +Save
• Table S1 from A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML
  2023 DOI: 10.1158/1078-0432.23553307
  +Save